| Literature DB >> 35875265 |
Zaheer A Qureshi1,2, Elina Shrestha2, Pravash Budhathoki2, Haider Ghazanfar2, Faryal Altaf2, Manjeet Dhallu3.
Abstract
Todd's paresis or phenomenon (TP) is a focal weakness in a part of the body after a seizure. Seizure is an abrupt change in behavior caused by the cerebral cortex's electrical hyper-synchronization of neuronal networks. After the seizure, there is usually a transition period from the ictal state to the pre-seizure baseline level of awareness and function, referred to as the postictal period. Postictal symptoms include many systems, including sensory, motor, and psychosis. This phenomenon is named after Robert Bentley Todd, who first described it. Todd's paresis can be confused with other conditions, most commonly a stroke. Postictal ocular manifestation may be accompanied by aphasia or hemiplegia, but isolated gaze palsy is rarely reported. We are reporting a rare and first known isolated ophthalmoparesis and ptosis as postictal findings with no structural abnormalities present in imaging studies and complete resolution over three weeks on its own as an atypical postictal phenomenon. Patients with an underlying structural abnormality of the brain are more susceptible to Todd's phenomenon. Unusual manifestations of Todd's phenomenon are rare but clinically relevant and are decisive in therapeutic decision-making. Our patient presents a rare manifestation of Todd's phenomenon as ptosis and ophthalmoparesis in an elderly male with no underlying structural brain abnormalities that resolved within three weeks. Further research into the causes is needed to distinguish it from a stroke.Entities:
Keywords: atypical todd; bilateral ptosis; medicine; neurology; ophthalmoparesis; opthalmology; postictal deficits; ptosis; seizure; todd's phenomenon
Year: 2022 PMID: 35875265 PMCID: PMC9298602 DOI: 10.7759/cureus.26108
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Initial laboratory results
| Laboratory Parameters | Results | Reference Range |
| White blood cells (k/ul) | 7.5 | 4.8-10.8 |
| Neutrophil % | 55.5 | 40 - 70 |
| Hemoglobin (g/dl) | 13.7 | 12.0-16.0 |
| Hematocrit (%) | 40.9 | 42.0-51.0 |
| Platelets (150-400 k/ul) | 171 | 150-440 |
| Prothrombin time (PT) (seconds) | 12.5 | 9.9 – 13.3 |
| Partial thromboplastin time (APTT) (seconds) | 29.6 | 27.2 – 39.6 |
| International normalized ratio (INR) | 1.08 | 0.85 – 1.14 |
| Sodium (mEq/L) | 140 | 135 - 145 |
| Potassium (mEq/L) | 3.5 | 3.5 – 5.0 |
| Serum chloride (mEq/L) | 104 | 98 - 108 |
| Serum bicarbonate (mEq/L) | 21 | 24 - 30 |
| Serum glucose (mg/dl) | 87 | 70 - 120 |
| Blood urea nitrogen (mg/dL) | 11 | 8 - 26 |
| Creatinine (mg/dL) | 0.8 | 8.5 – 10.5 |
| Total serum calcium (mg/dL) | 9.2 | 9 - 15 |
| Serum magnesium (mg/dL) | 1.8 | 1.5 – 2.7 |
| Total bilirubin (mg/dl) | 0.3 | 0.2 – 1.1 |
| Direct bilirubin (mg/dl) | 0.1 | 0.0 – 0.3 |
| Total serum protein (g/dl) | 6.8 | 5.8 – 8.3 |
| Serum albumin (g/dl) | 4.2 | 3.2 – 4.6 |
| Alanine aminotransferase (unit/l) | 18 | 5 – 40 |
| Aspartate transaminase (unit/l) | 26 | 9 – 48 |
| Serum alkaline phosphatase (unit/l) | 102 | 56 - 155 |
| Serum ethanol (mg/dL) | 96 | < = 10 mg/dL |
| Serum creatine kinase (unit/L) | 240 | 20 - 200 |
| Absolute CD4 count (cells/ul) | 844 cells/ul | 490 - 1740 |
| Human imunodeficiency virus (HIV) Ribonucleic acid (RNA) by polymerase chain reaction (PCR) copies/mL | 168 | Target not detected |
| Urine drug screen: | ||
| Cocaine | Negative | Negative |
| Cannabinoid | Negative | Negative |
| Benzodiazepine | Negative | Negative |
| Methadone | Negative | Negative |
| Opiate | Negative | Negative |
| Phencyclidine (PCP) | Negative | Negative |
Laboratory results for neuromuscular diseases
| Laboratory Parameters | Results | Reference Range |
| Thyroid stimulating hormone (mIU/l) | 1.78 | 0.40-4.50 |
| MUSK (Muscle Specific Kinase) antibody test | Negative | Negative |
| Acetylcholine receptor antibody (nmol/L) | <0.30 | < or =0.30 nmol/L |
| Lyme antibody by western blot | <0.90 | < 0.90 |
| Serum zinc (mcg/dL) | 70 | 60 - 130 |
| Serum copper (mcg/dl) | 108 | 70 - 175 |
Figure 1CT scan of the head showing normal architecture and no ischemic areas
CT: computed tomography
Figure 2T2/FLAIR MRI of the head showing normal architecture
FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging
Laboratory results of the CSP from the lumbar puncture
PCR: polymerase chain reaction; CSP: cerebrospinal fluid
| Cerebrospinal fluid (CSF) Analysis | Results | Reference Range |
| Color | Colorless | Colorless |
| Appearance | Clear | Clear |
| White blood count | 3 | 0 - 5 |
| Red blood cell count | 1 | 0 - 6 |
| Gram stain | No organism seen | No organism seen |
| Glucose (mg/dl) | 71 mg/dl | 40 - 70 |
| Protein (mg/dL) | 43 | 15 - 45 |
| Lactic acid (mmoles/L) | 1.4 | 0.6 -2.2 |
| Cryptococcal antigen | Not detected | Not detected |
| Bacterial antigen | Negative | Negative |
| Mycobacteria culture with fluorochrome | Negative | Negative |
| Miscellaneous fungal culture | Negative | Negative |
| Viral culture | Negative | Negative |
| Aerobic culture | Negative | Negative |
| Cytomegalovirus antibody, quantitative IU/mL | <200 IU/ml | < 200 |
| Herpes simplex virus-1 (HSV-1) and Herpes simplex virus-2 (HSV-2) quantitative, PCR | <100 copies/ml | <100 copies/ml |
| Venereal disease research laboratory test (VDRL) quantitative | Non-reactive | Non-reactive |